PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Medicine, Women\'s Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.\', \'Eli Lilly and Company, Indianapolis, Indiana, USA.\', \'Emory University, Atlanta, Georgia, USA.\', \'NYU Grossman School of Medicine, New York, New York, USA.\', \'The University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.\', \'Division of Gastroenterology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/cpt.2405
?:doi
?:hasPublicationType
?:journal
  • Clinical pharmacology and therapeutics
is ?:pmid of
?:pmid
?:pmid
  • 34455583
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.699
?:rankingScore_hIndex
  • 169
?:title
  • First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34455583>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34455583>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all